Lilly Broadens Its CNS Reach With Rigel RIPK1 Deal

Joins Sanofi And Denali In Class

 
• By Andrew McConaghie
  
Eli Lilly logo sign atop Lilly Biotechnology Center
Lilly has maintained neurodegeneration investment despite multiple failures - but new targets are bringing renewed hope of progress.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip